Huy Vu Nguyen, MD
Ophthalmology · West Covina
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Joseph L Lin MD Inc · 3 clinicians in this group
Hospitals listed: Pomona Valley Hospital Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Nguyen’s office at (626) 653-9444 to ask if they take your plan before you enroll.
California Medical Board record
Licence A161710 · Current
Licensed to practise in California · since 2019 · expires 2027-04-30 · Columbia University College of Physicians and Surgeons.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Pomona Valley Hospital Medical CenterPomona, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Pomona Valley Hospital Medical CenterPatients rate it 2 of 5 · 68% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.64 (0.33 to 0.96), Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.398, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.389, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.155, Oct 2024 – Sep 2025
See every measure and the patient survey for Pomona Valley Hospital Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 2 better, 9 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.64 (0.33 to 0.96) | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.398 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.389 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.155 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.85 (0 to 1.84) · 1,069 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 169.52 (120.62 to 218.41) · 65 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.7 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 51 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 110 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.2 · 369 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.5 · 190 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.7 · 583 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 3,744 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.35) · 5,235 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.42) · 5,161 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.2 (1.1 to 5.3) · 996 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.55 (0 to 3.22) · 180 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.88 (0.32 to 3.44) · 911 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.99 (0 to 12.42) · 189 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.25 (0.34 to 8.16) · 172 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.6 (0.14 to 3.05) · 196 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.1 (0 to 0.65) · 4,157 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 64 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.953 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.438 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 278 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.8 · 982 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -1.1 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -51.4 · 454 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -29.1 · 219 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.1 · 453 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 7.6) · 74 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.3 (9.5 to 18.1) · 74 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 57 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.9 · 97 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.5 · 137 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.5 (10.1 to 18) · 319 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 199 cases | No different | Jan 2024 – Dec 2024 |
What patients said (2,021 patients answered, 13% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 73% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 80% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 79% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$628,994
Medicare paid this office $628,994 for 404 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, faricimab-svoa, 0.1 mg | 41 | $300,848 | None |
| Injection, aflibercept, 1 mg | 11 | $60,593 | None |
| Established patient complete exam of visual system | 305 | $59,694 | $105 |
| Injection of drug into eye | 95 | $39,207 | $112 |
| Imaging of retina | 349 | $28,712 | $35 |
See all 12 services
| Injection, faricimab-svoa, 0.1 mg | 41 | $300,848 | None |
| Injection, aflibercept, 1 mg | 11 | $60,593 | None |
| Established patient complete exam of visual system | 305 | $59,694 | $105 |
| Injection of drug into eye | 95 | $39,207 | $112 |
| Imaging of retina | 349 | $28,712 | $35 |
| Established patient problem focused exam of visual system | 120 | $22,939 | $81 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 103 | $20,580 | $151 |
| New patient visit (45+ min) | 154 | $18,369 | $119 |
| Injection, bevacizumab, 10 mg | 63 | $9,162 | None |
| Extended exam of the back part of the eye with retinal drawing | 246 | $7,833 | $20 |
| Photography of the retina | 104 | $4,041 | $29 |
| 2d ultrasound scan of eye tissue and structures | 23 | $2,355 | $44 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Who their Medicare patients are
404 Original Medicare patients in 2024. Average age 74 · Under 65 8% · 85 and older 13% · Women 56% · Also on Medicaid 31% · Health risk score 1.58. Sicker patients than 9 in 10 peers; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 73% · Diabetes 44% · Coronary heart disease 29% · Chronic kidney disease 26% · Heart failure 18% · Depression 15% · Cancer 13% · Atrial fibrillation 13% · COPD 12% · Stroke 9% · Dementia 6%.
The office billed $1,422,269, Medicare allowed $810,520 and paid $628,994; for 14,374 services of 38 kinds; $386,901 of it was for drugs given in the office and $242,092 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 404 | 14,374 | 74 | 1.58 | $1,422,269 | $628,994 |
| 2023 | 348 | 4,565 | 73 | 1.54 | $905,953 | $363,984 |
| 2022 | 205 | 1,973 | 73 | 1.33 | $545,229 | $214,545 |
| 2021 | 115 | 278 | 76 | 1.27 | $110,541 | $22,871 |
| 2020 | 105 | 139 | 76 | 1.57 | $144,465 | $9,771 |
| 2019 | 63 | 82 | 73 | 1.59 | $96,501 | $5,822 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Injection, aflibercept, 1 mg | 24 | $120,023 | None |
| Injection, faricimab-svoa, 0.1 mg | 14 | $51,981 | None |
| Established patient complete exam of visual system | 223 | $45,829 | $102 |
| Injection of drug into eye | 68 | $25,406 | $105 |
| New patient visit (45+ min) | 201 | $25,002 | $124 |
| Imaging of retina | 292 | $20,706 | $34 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 93 | $14,422 | $124 |
| Extended exam of the back part of the eye with retinal drawing | 272 | $9,994 | $20 |
| Established patient problem focused exam of visual system | 54 | $7,855 | $78 |
| Injection, bevacizumab, 10 mg | 48 | $7,367 | None |
| Photocoagulation treatment to prevent detachment of retina | 14 | $3,643 | $214 |
| Photography of the retina | 94 | $3,259 | $28 |
| 2d ultrasound scan of eye tissue and structures | 27 | $1,872 | $43 |
2022: 11 services
| Injection, aflibercept, 1 mg | 18 | $78,837 | None |
| Established patient complete exam of visual system | 109 | $29,569 | $108 |
| Injection of drug into eye | 51 | $20,183 | $113 |
| New patient visit (45+ min) | 150 | $18,331 | $122 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 91 | $13,992 | $115 |
| Imaging of retina | 158 | $12,737 | $35 |
| Injection, bevacizumab, 10 mg | 47 | $6,547 | None |
| Extended exam of the back part of the eye with retinal drawing | 146 | $6,448 | $21 |
| Established patient problem focused exam of visual system | 42 | $6,000 | $76 |
| Photography of the retina | 91 | $3,377 | $28 |
| 2d ultrasound scan of eye tissue and structures | 17 | $976 | $42 |
2021: 9 services
| New patient visit (45+ min) | 32 | $4,373 | $137 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 28 | $2,608 | $90 |
| Injection of drug into eye | 12 | $2,059 | $108 |
| Short return visit (20+ min) | 44 | $2,041 | $46 |
| Established patient complete exam of visual system | 12 | $1,512 | $116 |
| Imaging of retina | 35 | $1,264 | $31 |
| Injection, bevacizumab, 10 mg | 11 | $957 | None |
| Photography of the retina | 21 | $685 | $33 |
| Extended exam of the back part of the eye with retinal drawing | 21 | $488 | $22 |
2020: 3 services
| Short return visit (20+ min) | 55 | $2,497 | $42 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 15 | $733 | $41 |
| Imaging of retina | 17 | $439 | $23 |
2019: 1 service
| Short return visit (20+ min) | 32 | $1,556 | $46 |
Medicaid work
$146,951 in 2024
Medicaid paid $146,951 for 3,063 billed services this clinician did in 2024, up to 77 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Intravitreal injection of a pharmacologic agent (separate procedure) | 431 | $68,862 |
| Injection, bevacizumab, 10 mg | 338 | $18,459 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 718 | $14,189 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 239 | $11,844 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 452 | $10,535 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 355 | $8,491 |
| New patient visit (45+ min) | 139 | $6,420 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 238 | $6,207 |
| Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral | 153 | $1,943 |
| 2024 | 3,063 | 9 | 77 | $146,951 |
| 2023 | 2,944 | 9 | 62 | $189,825 |
| 2022 | 2,142 | 9 | 61 | $135,669 |
See the largest Medicaid services in earlier years
2023
| Intravitreal injection of a pharmacologic agent (separate procedure) | 357 | $80,029 |
| Injection, bevacizumab, 10 mg | 278 | $19,558 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 480 | $18,236 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 642 | $18,035 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 180 | $14,115 |
| New patient visit (45+ min) | 199 | $11,363 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 222 | $10,355 |
| Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral | 401 | $10,304 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 185 | $7,831 |
2022
| Intravitreal injection of a pharmacologic agent (separate procedure) | 186 | $44,612 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 296 | $16,669 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 479 | $16,561 |
| New patient visit (45+ min) | 245 | $15,844 |
| Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral | 384 | $12,152 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 147 | $10,267 |
| Injection, bevacizumab, 10 mg | 145 | $7,852 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 151 | $6,246 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 109 | $5,465 |
Drugs they prescribed that Part D paid
$17,583
Pharmacies billed $17,583 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 418) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
253 generic and 165 brand-name prescriptions · $17,583 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Brimonidine | 40 | $2,499 | $62 |
| Prednisolone Acetate | 82 | $2,297 | $28 |
| Dorzolamide-Timolol | 62 | $1,024 | $17 |
| Latanoprost | 107 | $734 | $7 |
| Ketorolac Tromethamine | 21 | $658 | $31 |
See all 8 drugs
| Brimonidine | 40 | $2,499 | $62 |
| Prednisolone Acetate | 82 | $2,297 | $28 |
| Dorzolamide-Timolol | 62 | $1,024 | $17 |
| Latanoprost | 107 | $734 | $7 |
| Ketorolac Tromethamine | 21 | $658 | $31 |
| Moxifloxacin | 15 | $366 | $24 |
| Dorzolamide | 12 | $233 | $19 |
| Timolol Maleate | 17 | $136 | $8 |
Year by year
| 2024 | 418 | 116 | 0% (0) | 39% | $17,583 |
| 2023 | 318 | 78 | 0% (0) | 36% | $17,470 |
| 2022 | 186 | 61 | 0% (0) | 35% | $8,457 |
| 2021 | 74 | 39 | 0% (0) | 50% | $8,485 |
| 2020 | 220 | 82 | None | 53% | $41,291 |
| 2019 | 326 | 96 | 0% (0) | 48% | $114,869 |
| 2018 | 161 | 72 | None | 50% | $9,957 |
| 2017 | 73 | 50 | None | 34% | $4,523 |
| 2016 | 81 | 54 | None | None | $4,677 |
| 2015 | 35 | 17 | 0% (0) | None | $1,983 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Prednisolone Acetate | 47 | $1,661 | $35 |
| Dorzolamide-Timolol | 60 | $1,606 | $27 |
| Brimonidine | 28 | $1,552 | $55 |
| Latanoprost | 74 | $1,126 | $15 |
| Ketorolac Tromethamine | 22 | $556 | $25 |
| Dorzolamide | 18 | $372 | $21 |
2022: 5 drugs
| Prednisolone Acetate | 43 | $1,600 | $37 |
| Dorzolamide-Timolol | 20 | $699 | $35 |
| Latanoprost | 39 | $652 | $17 |
| Dorzolamide | 27 | $605 | $22 |
| Brimonidine | 11 | $163 | $15 |
2021: 2 drugs
| Prednisolone Acetate | 12 | $536 | $45 |
| Brimonidine | 14 | $109 | $8 |
2020: 8 drugs
| Timoptic Ocudose | 11 | $5,714 | $519 |
| Prednisolone Acetate | 31 | $1,579 | $51 |
| Timolol Maleate | 11 | $625 | $57 |
| Latanoprost | 28 | $591 | $21 |
| Dorzolamide-Timolol | 11 | $512 | $47 |
| Moxifloxacin | 12 | $340 | $28 |
| Prednisone | 14 | $204 | $15 |
| Brimonidine | 13 | $201 | $15 |
2019: 6 drugs
| Prednisolone Acetate | 51 | $3,709 | $73 |
| Moxifloxacin | 52 | $2,738 | $53 |
| Ketorolac Tromethamine | 44 | $1,300 | $30 |
| Dorzolamide-Timolol | 28 | $1,069 | $38 |
| Latanoprost | 42 | $889 | $21 |
| Brimonidine | 13 | $871 | $67 |
2018: 5 drugs
| Ilevro | 13 | $4,160 | $320 |
| Prednisolone Acetate | 44 | $1,538 | $35 |
| Moxifloxacin | 16 | $671 | $42 |
| Ketorolac Tromethamine | 17 | $366 | $22 |
| Erythromycin | 19 | $223 | $12 |
Money from drug and device companies
$282 in 2025
| 2025 | 3 | 10 | None | $282 |
| 2024 | 4 | 13 | None | $395 |
| 2023 | 3 | 4 | None | $122 |
| 2022 | 5 | 5 | None | $210 |
| 2021 | 4 | 6 | None | $430 |
| 2020 | 1 | 2 | None | $27 |
| 2019 | 3 | 10 | None | $1,763 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Astellas Pharma US | Izervay | $172 | 6 payments
|
| Genentech USA | Vabysmo | $84 | 3 payments
|
| ANI Pharmaceuticals | Iluvien | $26 | 1 payment
|
See all 10 published payments
| Genentech USA | Meals · 2025-10-31 | Vabysmo | $26 |
| Astellas Pharma US | Meals · 2025-10-24 | Izervay | $33 |
| ANI Pharmaceuticals | Meals · 2025-10-16 | Iluvien | $26 |
| Astellas Pharma US | Meals · 2025-09-26 | Izervay | $33 |
| Astellas Pharma US | Meals · 2025-08-22 | Izervay | $29 |
| Genentech USA | Meals · 2025-08-07 | Vabysmo | $38 |
| Genentech USA | Meals · 2025-07-17 | Vabysmo | $20 |
| Astellas Pharma US | Meals · 2025-07-11 | Izervay | $29 |
| Astellas Pharma US | Meals · 2025-01-23 | Izervay | $30 |
| Astellas Pharma US | Meals · 2025-01-15 | Izervay | $18 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $395
| Astellas Pharma US | Izervay | $255 | 7 payments
|
| Genentech USA | Vabysmo | $101 | 4 payments
|
| Alimera Sciences | Yutiq | $22 | 1 payment
|
| Biogen | Byooviz | $17 | 1 payment
|
2023: $122
| Genentech USA | Vabysmo | $61 | 2 payments
|
| Apellis Pharmaceuticals | Syfovre | $31 | 1 payment
|
| Astellas Pharma US | None | $30 | 1 payment
|
2022: $210
| Horizon Therapeutics plc | Tepezza | $73 | 1 payment
|
| Alimera Sciences | Iluvien | $62 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $32 | 1 payment
|
| Genentech USA | Susvimo | $26 | 1 payment
|
| Abbvie | Ozurdex | $18 | 1 payment
|
2021: $430
| Alimera Sciences | Iluvien | $160 | 2 payments
|
| Allergan | Ozurdex | $139 | 2 payments
|
| Regeneron Healthcare Solutions | Eylea | $115 | 1 payment
|
| AbbVie | Ubrelvy | $15 | 1 payment
|
2020: $27
| Allergan | Ubrelvy | $27 | 2 payments
|
2019: $1,763
| Alcon Vision | Dailies | $1,396 | 7 payments
|
| Alimera Sciences | Iluvien | $250 | 2 payments
|
| Aerie Pharmaceuticals | Rhopressa | $117 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1497140446
- Licence
- CA A161710California A161710: Current · expires 2027-04-30
- Trained
- Columbia University College of Physicians and Surgeons, 2015
- Group
- Joseph L Lin MD Inc
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2015-04-06
- NPI last updated
- 2019-07-02
This is when the NPI record was last certified, not a medical board exam.